Hematological indices in congenital male hypogonadism and the effects of testosterone replacement therapy: a retrospective study

Özet

Aims: Mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), and neutrophil-tolymphocyteratio (NLR) are surrogate markers of adverse cardiovascular (CV) outcomes. Theaim of this study was to investigate the platelet count, MPV level, PLR, NLR, and the effectof testosterone replacement therapy (TRT) on these parameters in patients with congenitalhypogonadotropic hypogonadism (CHH).Methods: Young male patients with CHH and healthy controls were recruited from theoutpatient setting. Blood pressures, height, weight, waist circumference (WC), and blood testsincluding triglyceride (TG) level, insulin, homeostatic model assessment-insulin resistance(HOMA-IR), PLR, and NLR were calculated between CHH patients and controls and followingTRT.Results: Sixty-six patients with CHH (mean age: 21.5±2.0 years) and 67 healthy controls(mean age: 21.9±1.3 years) were included in the study. CHH patients had higher plateletcount (262.9±50.7 vs 232.1±49.2, p=0.001), MPV level (8.63±0.87 vs 8.16±0.92, p=0.004), PLR(114.01±25.68 vs 100.59±25.49, p=0.003), WC (86.8±9.1 vs 83.7±7.9, p=0.04), TG (96.0 vs 80.0,p=0.02), insulin (9.41 vs 6.92, p<0.001), and HOMA-IR (1.95 vs 1.47, p<0.001) than healthycontrols. NLR was similar in both groups. After TRT, CHH patients showed significant elevationsin body mass index, WC, total testosterone, and HOMA-IR and reduction in high densitylipoprotein cholesterol level; however, platelet count, MPV, PLR, and NLR indices remainedunchanged. Total testosterone level was also correlated with platelet count, MPV, and PLR.Conclusions: This study showed higher platelet count and surrogate markers of CV risk such asMPV and PLR in patients with CHH. However, short time TRT did not show any effect on theseindices.